



## Clinical trial results:

**A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA. The “RELEVANCE” trial**

### Summary

EudraCT number	2011-002792-42
Trial protocol	BE IT DE PT ES
Global end of trial date	30 April 2024

### Results information

Result version number	v1 (current)
This version publication date	15 May 2025
First version publication date	15 May 2025

### Trial information

#### Trial identification

Sponsor protocol code	RV-FOL-GELARC-0683C / RELEVANCE
-----------------------	---------------------------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	LYSARC
Sponsor organisation address	CH Lyon Sud Bâtiment 2D, Pierre Bénite, France, 69945
Public contact	LYSARC, LYSARC, affaires-reglementaires@lysarc.org
Scientific contact	LYSARC, LYSARC, affaires-reglementaires@lysarc.org

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 October 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 April 2024
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To compare the efficacy of rituximab plus lenalidomide to rituximab plus chemotherapy followed by rituximab in patients with previously untreated follicular lymphoma.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 December 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	France: 581
Country: Number of subjects enrolled	Belgium: 65
Country: Number of subjects enrolled	Spain: 58
Country: Number of subjects enrolled	Portugal: 13
Country: Number of subjects enrolled	Italy: 5
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	Canada: 46
Country: Number of subjects enrolled	United States: 221
Country: Number of subjects enrolled	Japan: 34
Country: Number of subjects enrolled	Australia: 3
Worldwide total number of subjects	1030
EEA total number of subjects	726

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	701
From 65 to 84 years	327
85 years and over	2

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

1030 participants were randomized, 1010 were treated

### Period 1

Period 1 title	Pre-treatment
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Rituximab-Lenalidomide
------------------	------------------------

Arm description:

Rituximab, 375 mg/m<sup>2</sup> on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.

Arm type	Experimental
Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

375 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of cycle 1; then

375 mg/m<sup>2</sup> on day 1 of cycles 2-6; then responders only: 375mg/m<sup>2</sup> every 8 weeks for 12 cycles.

Investigational medicinal product name	Lenalidomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

20 mg/day on days 2-22 for 6 cycles

<b>Arm title</b>	Investigator Choice
------------------	---------------------

Arm description:

Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m<sup>2</sup> rituximab and 7 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m<sup>2</sup> (day 1) plus bendamustine 90 mg/m<sup>2</sup> (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles.

Arm type	Active comparator
Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:  
 375 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of cycle 1; then  
 375 mg/m<sup>2</sup> on day 1 of cycles 2-6; then responders only: 375mg/m<sup>2</sup> every 8 weeks for 12 cycles.

Investigational medicinal product name	CHOP - Vincristine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Six cycles of R-CHOP in 21-day cycles:  
 Vincristine, 1.4 mg/m<sup>2</sup> (2 mg cap) IV on day 1

Investigational medicinal product name	CHOP - Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Six cycles of R-CHOP in 21-day cycles:  
 Prednisone, 100 mg/day PO on days 1-5

Investigational medicinal product name	Bendamustine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

90mg/m<sup>2</sup> on days 1 + 2 every 28 days for six cycles

Investigational medicinal product name	CVP- Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Eight cycles of R-CVP in 21-day cycles:  
 Prednisone, 100 mg/day PO on days 1-5

Investigational medicinal product name	CVP - Cyclophosphamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Eight cycles of R-CVP in 21-day cycles  
 Cyclophosphamide 750 mg/m<sup>2</sup> day 1

Investigational medicinal product name	CVP - Vincristine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Eight cycles of R-CVP in 21 day cycles  
 Vincristine 1.4 mg/m<sup>2</sup> (2mgcap) day 1,

Investigational medicinal product name	CHOP - Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion

Routes of administration	Intravenous use
Dosage and administration details:	
Six cycles of R-CHOP in 21-day cycles:	
Doxorubicin,50mg/m <sup>2</sup> IV on day 1	
Investigational medicinal product name	CHOP - Cyclophosphamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Six cycles of R-CHOP in 21-day cycles:	
Cyclophosphamide,750mg/m <sup>2</sup> IV on day 1	

Number of subjects in period 1	Rituximab-Lenalidomide	Investigator Choice
Started	513	517
Completed	507	503
Not completed	6	14
Other reasons	6	14

## Period 2

Period 2 title	Treatment
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
Arm title	Rituximab-Lenalidomide

### Arm description:

Rituximab, 375 mg/m<sup>2</sup> on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.

Arm type	Experimental
Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

### Dosage and administration details:

375 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of cycle 1; then  
375 mg/m<sup>2</sup> on day 1 of cycles 2-6; then responders only: 375mg/m<sup>2</sup> every 8 weeks for 12 cycles.

Investigational medicinal product name	Lenalidomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule

Routes of administration	Oral use
--------------------------	----------

Dosage and administration details:  
20 mg/day on days 2-22 for 6 cycles

<b>Arm title</b>	Investigator Choice
------------------	---------------------

Arm description:

Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m<sup>2</sup> rituximab and 7 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m<sup>2</sup> (day 1) plus bendamustine 90 mg/m<sup>2</sup> (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles.

Arm type	Active comparator
Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

375 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of cycle 1; then  
375 mg/m<sup>2</sup> on day 1 of cycles 2-6; then responders only: 375mg/m<sup>2</sup> every 8 weeks for 12 cycles.

Investigational medicinal product name	CHOP - Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Six cycles of R-CHOP in 21-day cycles:  
Doxorubicin, 50mg/m<sup>2</sup> IV on day 1

Investigational medicinal product name	CHOP - Vincristine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Six cycles of R-CHOP in 21-day cycles:  
Vincristine, 1.4 mg/m<sup>2</sup> (2 mg cap) IV on day 1

Investigational medicinal product name	CHOP - Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Six cycles of R-CHOP in 21-day cycles:  
Prednisone, 100 mg/day PO on days 1-5

Investigational medicinal product name	Bendamustine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

90mg/m<sup>2</sup> on days 1 + 2 every 28 days for six cycles

Investigational medicinal product name	CVP- Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Eight cycles of R-CVP in 21-day cycles: Prednisone, 100 mg/day PO on days 1-5	
Investigational medicinal product name	CVP - Cyclophosphamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Eight cycles of R-CVP in 21-day cycles Cyclophosphamide 750 mg/m <sup>2</sup> day 1	
Investigational medicinal product name	CVP - Vincristine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Eight cycles of R-CVP in 21 day cycles Vincristine 1.4 mg/m <sup>2</sup> (2mgcap) day 1,	
Investigational medicinal product name	CHOP - Cyclophosphamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Six cycles of R-CHOP in 21-day cycles: Cyclophosphamide, 750mg/m <sup>2</sup> IV on day 1	

Number of subjects in period 2	Rituximab-Lenalidomide	Investigator Choice
Started	507	503
Completed	350	357
Not completed	157	146
Adverse event, serious fatal	-	1
Consent withdrawn by subject	3	14
Toxicity	44	16
Major protocol violation	1	6
Voluntary treatment discontinuation	8	4
Progression	64	71
Concurrent illness	12	9
Other reasons	10	22
Insufficient response	15	3





## Baseline characteristics

### Reporting groups

Reporting group title	Rituximab-Lenalidomide
-----------------------	------------------------

Reporting group description:

Rituximab, 375 mg/m<sup>2</sup> on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.

Reporting group title	Investigator Choice
-----------------------	---------------------

Reporting group description:

Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m<sup>2</sup> rituximab and 7 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m<sup>2</sup> (day 1) plus bendamustine 90 mg/m<sup>2</sup> (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles.

Reporting group values	Rituximab-Lenalidomide	Investigator Choice	Total
Number of subjects	513	517	1030
Age categorical			
Units: Subjects			
Adults (18-64 years)	348	353	701
From 65-84 years	163	164	327
85 years and over	2	0	2
Age Continuous			
Units: Years			
arithmetic mean	58.5	58.3	
standard deviation	± 11.23	± 11.38	-
Sex: Female, Male			
Units: Participants			
Female	262	266	528
Male	251	251	502

## End points

### End points reporting groups

Reporting group title	Rituximab-Lenalidomide
Reporting group description: Rituximab, 375 mg/m <sup>2</sup> on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m <sup>2</sup> rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.	
Reporting group title	Investigator Choice
Reporting group description: Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m <sup>2</sup> rituximab and 7 weeks later responding patients continue with 375 mg/m <sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m <sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m <sup>2</sup> (day 1) plus bendamustine 90 mg/m <sup>2</sup> (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m <sup>2</sup> rituximab every 8 weeks for 12 cycles.	
Reporting group title	Rituximab-Lenalidomide
Reporting group description: Rituximab, 375 mg/m <sup>2</sup> on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m <sup>2</sup> rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.	
Reporting group title	Investigator Choice
Reporting group description: Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m <sup>2</sup> rituximab and 7 weeks later responding patients continue with 375 mg/m <sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m <sup>2</sup> rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m <sup>2</sup> (day 1) plus bendamustine 90 mg/m <sup>2</sup> (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m <sup>2</sup> rituximab every 8 weeks for 12 cycles.	

### Primary: Complete Response Rate (CR/CRu) at 120 weeks by Independent Central Review

End point title	Complete Response Rate (CR/CRu) at 120 weeks by Independent Central Review
End point description: The Complete Response Rate (CR/CRu) is the percentage of participants who achieve complete response (CR/CRu) at 120 weeks as assessed per Independent Central Review. - Complete Response (CR): Disappearance of all evidence of disease. - Complete Response Unconfirmed (CRu): Disappearance of all disease with the exception of residual lymph nodes that are 1.5 cm or less in greatest transverse diameter and/or indeterminate bone marrow findings.	
End point type	Primary
End point timeframe: At 120 weeks	

End point values	Rituximab-Lenalidomide	Investigator Choice		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	513	517		
Units: Percent of participants				
number (confidence interval 95%)	48.1 (43.7 to 52.6)	53.0 (48.6 to 57.4)		

## Statistical analyses

Statistical analysis title	Complete Response Rate (CR/CRu) at 120 Weeks
Comparison groups	Rituximab-Lenalidomide v Investigator Choice
Number of subjects included in analysis	1030
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.128
Method	Cochran-Mantel-Haenszel

## Primary: Progression-free Survival (PFS)

End point title	Progression-free Survival (PFS)
End point description:	
<p>Progression-free survival (PFS) is defined as the time from randomization into the study to the first observation of documented disease progression or death due to any cause.</p> <p>Progressive Disease (PD) is characterized by any of the following:</p> <ul style="list-style-type: none"> <li>-An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites.</li> <li>-The appearance of any new lesion during or after treatment.</li> <li>-An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis.</li> <li>-An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly).</li> </ul> <p>Based on Kaplan-Meier estimates. Censoring rules based on EMA guidelines.</p> <p>"99999"=N/A</p>	
End point type	Primary
End point timeframe:	
From randomization into the study to the first observation of documented disease progression or death due to any cause (up to approximately 140 months).	

End point values	Rituximab-Lenalidomide	Investigator Choice		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	513	517		
Units: Months				
median (confidence interval 95%)	110.6 (85.5 to 122.1)	102.8 (83.4 to 123.5)		

## Statistical analyses

<b>Statistical analysis title</b>	Progression-free Survival (PFS)
Comparison groups	Rituximab-Lenalidomide v Investigator Choice
Number of subjects included in analysis	1030
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.499
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.785
upper limit	1.125

## Secondary: Complete Response Rate (CR) at 120 weeks per Independent Central Review

End point title	Complete Response Rate (CR) at 120 weeks per Independent Central Review
End point description: The Complete Response Rate (CR) is the percentage of participants who achieve complete response (CR) at 120 weeks as assessed per Independent Central Review. - Complete Response (CR): Disappearance of all evidence of disease.	
End point type	Secondary
End point timeframe: At 120 weeks	

End point values	Rituximab-Lenalidomide	Investigator Choice		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	513	517		
Units: Percent of participants				
number (confidence interval 95%)	27.7 (23.8 to 31.8)	32.7 (28.7 to 36.9)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Event-free Survival (EFS)

End point title	Event-free Survival (EFS)
End point description: Event Free Survival (EFS) is the time a participant remains free from certain negative events (disease progression, relapse, initiation of a new anti-lymphoma treatment, or death) between the date of	

randomization to the date of first documented progression, relapse, and initiation of a new anti-lymphoma treatment or death by any cause. Responding participants and those lost to follow up were censored at their last tumor assessment date.

Progressive Disease (PD) is characterized by any of the following:

- An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites.

- The appearance of any new lesion during or after treatment.

- An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis.

- An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly).

Based on Kaplan-Meier estimates.

"99999"=N/A

End point type	Secondary
End point timeframe:	
From randomization to the date of first documented progression, relapse, and initiation of a new anti-lymphoma treatment or death by any cause (up to approximately 140 months).	

End point values	Rituximab-Lenalidomide	Investigator Choice		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	513	517		
Units: Months				
median (confidence interval 95%)	130.6 (121.9 to 99999)	132.3 (115.7 to 99999)		

## Statistical analyses

Statistical analysis title	Event Free Survival (EFS)
Comparison groups	Rituximab-Lenalidomide v Investigator Choice
Number of subjects included in analysis	1030
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Hazard ratio (HR)
Point estimate	1.038
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.854
upper limit	1.261

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

Overall survival (OS) is defined as the median length of time a participant stays alive from randomization. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who withdrew consent for the study were considered censored at the time of withdrawal. Participants who completed the study and were still alive at the time of the clinical data cut-off date were censored. All participants who were lost to follow-up prior to the clinical data cut-off date were also considered censored at the time of last contact. Based on Kaplan-Meier estimates.

"99999"=N/A

End point type	Secondary
End point timeframe:	
From randomization to the date of death by any cause (up to approximately 144 months).	

<b>End point values</b>	Rituximab-Lenalidomide	Investigator Choice		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	513	517		
Units: Months				
median (confidence interval 95%)	99999 (-99999 to 99999)	99999 (-99999 to 99999)		

### Statistical analyses

<b>Statistical analysis title</b>	Overall survival (OS)
Comparison groups	Rituximab-Lenalidomide v Investigator Choice
Number of subjects included in analysis	1030
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Hazard ratio (HR)
Point estimate	1.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.775
upper limit	1.395

### Secondary: Time to Next Anti-Lymphoma Treatment (TTNLT)

End point title	Time to Next Anti-Lymphoma Treatment (TTNLT)
End point description:	
Time to Next Lymphoma Treatment (TTNLT) was measured from the date of randomization to the date of the first documented administration of any new anti-lymphoma treatment (such as chemotherapy, radiotherapy, radio-immunotherapy, or immunotherapy). Participants who continued to respond to treatment or who were lost to follow-up were considered censored on their last visit date. Participants who died (due to any cause) before receiving a new anti-lymphoma treatment were included in the statistical analysis, with death being counted as an event. Based on Kaplan-Meier estimates. "99999"=N/A	
End point type	Secondary
End point timeframe:	
From the date of randomization to the date of the first documented administration of any new anti-lymphoma treatment (up to approximately 140 months).	

<b>End point values</b>	Rituximab-Lenalidomide	Investigator Choice		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	513	517		
Units: Months				
median (confidence interval 95%)	99999 (-99999 to 99999)	99999 (-99999 to 99999)		

## Statistical analyses

<b>Statistical analysis title</b>	Time to Next Anti-Lymphoma Treatment (TTNLT)
Comparison groups	Rituximab-Lenalidomide v Investigator Choice
Number of subjects included in analysis	1030
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	0.809
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.651
upper limit	1.006



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Death was assessed from first dose to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (an average of 25 months and a maximum of 33 months).

Adverse event reporting additional description:

The number at Risk for death, Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	27.0

### Reporting groups

Reporting group title	Investigator's Choice: Rituximab-CHOP
-----------------------	---------------------------------------

Reporting group description:

Six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m<sup>2</sup> rituximab and 7 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles.

Reporting group title	Investigator's Choice: Rituximab-CVP
-----------------------	--------------------------------------

Reporting group description:

Eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles.

Reporting group title	Rituximab-Lenalidomide
-----------------------	------------------------

Reporting group description:

Rituximab, 375 mg/m<sup>2</sup> on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.

Reporting group title	Investigator's Choice: Rituximab-Bendamustine
-----------------------	---

Reporting group description:

Rituximab 375 mg/m<sup>2</sup> (day 1) plus bendamustine 90 mg/m<sup>2</sup> (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m<sup>2</sup> rituximab every 8 weeks for 12 cycles.

Serious adverse events	Investigator's Choice: Rituximab-CHOP	Investigator's Choice: Rituximab-CVP	Rituximab-Lenalidomide
Total subjects affected by serious adverse events			
subjects affected / exposed	109 / 365 (29.86%)	7 / 26 (26.92%)	181 / 507 (35.70%)
number of deaths (all causes)	69	6	87
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
ACUTE LYMPHOCYTIC LEUKAEMIA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

ADENOCARCINOMA OF COLON			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CLEAR CELL RENAL CELL CARCINOMA			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BENIGN NEOPLASM OF EPIDIDYMIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BENIGN RENAL NEOPLASM			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BOWEN'S DISEASE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BREAST CANCER			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BASAL CELL CARCINOMA			
subjects affected / exposed	5 / 365 (1.37%)	0 / 26 (0.00%)	4 / 507 (0.79%)
occurrences causally related to treatment / all	1 / 5	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLON CANCER			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLORECTAL ADENOMA			

subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ENDOMETRIAL CANCER			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GALLBLADDER ADENOCARCINOMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INVASIVE DUCTAL BREAST CARCINOMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LYMPHOPROLIFERATIVE DISORDER			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LARYNGEAL SQUAMOUS CELL CARCINOMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUNG ADENOCARCINOMA			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUNG NEOPLASM MALIGNANT			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUNG SQUAMOUS CELL CARCINOMA STAGE III			

subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
KERATOACANTHOMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MALIGNANT MELANOMA			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENINGIOMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENINGIOMA BENIGN			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NON-SMALL CELL LUNG CANCER			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PAPILLARY THYROID CANCER			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA OF SKIN			
subjects affected / exposed	1 / 365 (0.27%)	1 / 26 (3.85%)	4 / 507 (0.79%)
occurrences causally related to treatment / all	0 / 1	0 / 1	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RENAL CANCER			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKIN CANCER			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL CELL LUNG CANCER METASTATIC			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA OF LUNG			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL ADENOCARCINOMA			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA OF THE CERVIX			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA OF THE TONGUE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

TUMOUR FLARE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	5 / 507 (0.99%)
occurrences causally related to treatment / all	0 / 0	0 / 0	5 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UTERINE LEIOMYOMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
AORTIC ANEURYSM RUPTURE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
AORTIC DISSECTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ARTERIAL THROMBOSIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ARTERIOVENOUS FISTULA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOTENSION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BLEEDING VARICOSE VEIN			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEEP VEIN THROMBOSIS			

subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAEMATOMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ARTERITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PHLEBITIS			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VASCULITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUPERFICIAL VEIN THROMBOSIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOSIS			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PHLEBITIS SUPERFICIAL			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
UMBILICAL HERNIA REPAIR			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
CHEST PAIN			
subjects affected / exposed	2 / 365 (0.55%)	1 / 26 (3.85%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 2	0 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASTHENIA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ADVERSE DRUG REACTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC DEATH			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
FATIGUE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



FOREIGN BODY REACTION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GENERAL PHYSICAL HEALTH DETERIORATION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	4 / 507 (0.79%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTHERMIA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MALAISE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUCOSAL INFLAMMATION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYREXIA			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	13 / 507 (2.56%)
occurrences causally related to treatment / all	1 / 2	0 / 0	7 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
STRANGULATED HERNIA			

subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FACE OEDEMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
ANAPHYLACTIC SHOCK			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAPHYLACTIC REACTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERSENSITIVITY			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DRUG HYPERSENSITIVITY			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAPHYLACTOID REACTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
CYSTOCELE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

PENILE ADHESION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PROSTATITIS			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
ACUTE PULMONARY OEDEMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASTHMA			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LARYNGEAL OEDEMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COUGH			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPNOEA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

INTERSTITIAL LUNG DISEASE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRONCHOPNEUMOPATHY			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUNG DISORDER			
subjects affected / exposed	1 / 365 (0.27%)	1 / 26 (3.85%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	3 / 3	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	9 / 507 (1.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	4 / 10
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
PLEURITIC PAIN			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONITIS			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	5 / 507 (0.99%)
occurrences causally related to treatment / all	0 / 2	0 / 0	5 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
PULMONARY OEDEMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RESPIRATORY FAILURE			

subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
CONVERSION DISORDER			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BIPOLAR DISORDER			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEPRESSION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MANIA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
DEVICE BREAKAGE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
PORTAL VEIN THROMBOSIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

HEPATITIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLECYSTITIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLECYSTITIS ACUTE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BILIARY DILATATION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BILIARY OBSTRUCTION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLANGITIS ACUTE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLELITHIASIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
ELECTROCARDIOGRAM T WAVE INVERSION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

TROPONIN INCREASED			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TROPONIN T INCREASED			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINE OUTPUT DECREASED			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
WEIGHT DECREASED			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FIBRIN D DIMER INCREASED			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
AORTIC INJURY			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ACCIDENTAL OVERDOSE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHEST INJURY			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

FALL			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEMUR FRACTURE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAND FRACTURE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HUMERUS FRACTURE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INCISIONAL HERNIA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFUSION RELATED REACTION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	9 / 507 (1.78%)
occurrences causally related to treatment / all	1 / 1	0 / 0	9 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LIGAMENT RUPTURE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MULTIPLE INJURIES			



subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POSTOPERATIVE WOUND COMPLICATION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RADIUS FRACTURE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL COLUMN INJURY			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL COMPRESSION FRACTURE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL FRACTURE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ULNA FRACTURE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
GASTROINTESTINAL MALFORMATION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

BRUGADA SYNDROME			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ACUTE CORONARY SYNDROME			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIOMYOPATHY			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC FAILURE			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC ARREST			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
BRADYCARDIA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ATRIOVENTRICULAR BLOCK COMPLETE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

ATRIAL FLUTTER			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ATRIAL FIBRILLATION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	3 / 507 (0.59%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ARRHYTHMIA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
AORTIC VALVE INCOMPETENCE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIORENAL SYNDROME			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANGINA PECTORIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SINUS NODE DYSFUNCTION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERICARDIAL EFFUSION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PALPITATIONS			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYOCARDIAL ISCHAEMIA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYOCARDIAL INFARCTION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
CORONARY ARTERY STENOSIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIOTOXICITY			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
MIGRAINE WITH AURA			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CEREBRAL INFARCTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CEREBROVASCULAR ACCIDENT			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	3 / 507 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEADACHE			

subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ISCHAEMIC STROKE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARPAL TUNNEL SYNDROME			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OPTIC NEURITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SCIATICA			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPEECH DISORDER			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRANSIENT ISCHAEMIC ATTACK			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			

subjects affected / exposed	1 / 365 (0.27%)	1 / 26 (3.85%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>AGRANULOCYTOSIS</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>EOSINOPHILIA</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>FEBRILE BONE MARROW APLASIA</b>			
subjects affected / exposed	3 / 365 (0.82%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	4 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>FEBRILE NEUTROPENIA</b>			
subjects affected / exposed	17 / 365 (4.66%)	1 / 26 (3.85%)	9 / 507 (1.78%)
occurrences causally related to treatment / all	18 / 19	1 / 1	8 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>NEUTROPENIA</b>			
subjects affected / exposed	3 / 365 (0.82%)	0 / 26 (0.00%)	3 / 507 (0.59%)
occurrences causally related to treatment / all	1 / 3	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PANCYTOPENIA</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>THROMBOCYTOPENIA</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	3 / 507 (0.59%)
occurrences causally related to treatment / all	1 / 1	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>IRON DEFICIENCY ANAEMIA</b>			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
VERTIGO			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
RETINAL DETACHMENT			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PAPILLOEDEMA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CATARACT			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
ABDOMINAL PAIN UPPER			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN			
subjects affected / exposed	3 / 365 (0.82%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	1 / 3	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIARRHOEA			
subjects affected / exposed	3 / 365 (0.82%)	0 / 26 (0.00%)	4 / 507 (0.79%)
occurrences causally related to treatment / all	2 / 3	0 / 0	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

ASCITES			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLITIS			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLITIS ISCHAEMIC			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONSTIPATION			
subjects affected / exposed	3 / 365 (0.82%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTRITIS			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FAECALOMA			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ENTEROCOLITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIVERTICULUM INTESTINAL			



subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>GASTROINTESTINAL PAIN</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>OESOPHAGITIS</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>NAUSEA</b>			
subjects affected / exposed	3 / 365 (0.82%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>INTESTINAL OBSTRUCTION</b>			
subjects affected / exposed	1 / 365 (0.27%)	1 / 26 (3.85%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>INGUINAL HERNIA</b>			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HERNIAL EVENTRATION</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PANCREATITIS</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PANCREATITIS ACUTE</b>			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POOR DENTAL CONDITION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOMITING			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	3 / 3	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUBILEUS			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
CUTANEOUS VASCULITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CAPILLARITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ECZEMA			

subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERSENSITIVITY VASCULITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPHILIC DERMATOSIS			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RASH			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	10 / 507 (1.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	5 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VASCULAR PURPURA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RASH PAPULAR			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
STEVENS-JOHNSON SYNDROME			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TOXIC SKIN ERUPTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	3 / 507 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URTICARIA			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RASH MACULO-PAPULAR			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	2 / 365 (0.55%)	1 / 26 (3.85%)	3 / 507 (0.59%)
occurrences causally related to treatment / all	0 / 2	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CALCULUS URINARY			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CYSTITIS HAEMORRHAGIC			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY RETENTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYDRONEPHROSIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEPHROLITHIASIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POLLAKIURIA			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>RENAL FAILURE</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	5 / 507 (0.99%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
<b>RENAL TUBULAR NECROSIS</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HAEMATURIA</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Endocrine disorders</b>			
<b>HYPERTHYROIDISM</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
<b>ARTHRALGIA</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BACK PAIN</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	3 / 507 (0.59%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BONE PAIN</b>			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

OSTEONECROSIS OF JAW			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FLANK PAIN			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INTERVERTEBRAL DISC PROTRUSION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NECK PAIN			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OSTEOARTHRITIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHONDROCALCINOSIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SOFT TISSUE NECROSIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL STENOSIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPONDYLITIS			

subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>CELLULITIS</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CAMPYLOBACTER SEPSIS</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BRONCHITIS</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BRONCHIOLITIS</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BACTERIURIA</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BACTERIAL SEPSIS</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>APPENDICITIS</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CLOSTRIDIUM DIFFICILE INFECTION</b>			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ESCHERICHIA SEPSIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
ERYSIPELAS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ENTEROBACTER SEPSIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEVICE RELATED SEPSIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROENTERITIS VIRAL			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROENTERITIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GANGRENE			



subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FUSOBACTERIUM INFECTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GENITAL HERPES SIMPLEX			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
H1N1 INFLUENZA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OESOPHAGEAL CANDIDIASIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENINGITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LARGE INTESTINE INFECTION			
subjects affected / exposed	1 / 365 (0.27%)	1 / 26 (3.85%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFLUENZA			
subjects affected / exposed	2 / 365 (0.55%)	1 / 26 (3.85%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 2	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFECTION			

subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HUMAN EHRLICHIOSIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HERPES ZOSTER			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HERPES OPHTHALMIC			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEPATITIS E			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PARONYCHIA			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA HAEMOPHILUS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA PNEUMOCOCCAL			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA STAPHYLOCOCCAL			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA STREPTOCOCCAL			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA VIRAL			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOCYSTIS JIROVECI PNEUMONIA			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PILONIDAL DISEASE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PHARYNGITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERITONITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
subjects affected / exposed	6 / 365 (1.64%)	0 / 26 (0.00%)	11 / 507 (2.17%)
occurrences causally related to treatment / all	3 / 6	0 / 0	4 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PSEUDOMONAL SEPSIS			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PSEUDOMONAS INFECTION			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TOOTH ABSCESS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TONSILLITIS			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SOFT TISSUE INFECTION			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SINUSITIS			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPTIC SHOCK			
subjects affected / exposed	2 / 365 (0.55%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	1 / 2	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
RESPIRATORY TRACT INFECTION			

subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYELONEPHRITIS ACUTE			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYELONEPHRITIS			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
WOUND INFECTION STAPHYLOCOCCAL			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
WOUND INFECTION BACTERIAL			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UROSEPSIS			
subjects affected / exposed	0 / 365 (0.00%)	1 / 26 (3.85%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION ENTEROCOCCAL			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	5 / 507 (0.99%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UPPER RESPIRATORY TRACT INFECTION			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>VIRAL INFECTION</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>DECREASED APPETITE</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DEHYDRATION</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DIABETES MELLITUS</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DIABETES MELLITUS INADEQUATE CONTROL</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DIABETIC KETOACIDOSIS</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYPONATRAEMIA</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYPERGLYCAEMIA</b>			

subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYPERKALAEMIA</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	0 / 507 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYPOALBUMINAEMIA</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYPOKALAEMIA</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYPERCALCAEMIA</b>			
subjects affected / exposed	1 / 365 (0.27%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>MALNUTRITION</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	1 / 507 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>TUMOUR LYSIS SYNDROME</b>			
subjects affected / exposed	0 / 365 (0.00%)	0 / 26 (0.00%)	3 / 507 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Investigator's Choice: Rituximab-Bendamustine		
Total subjects affected by serious adverse events			
subjects affected / exposed	32 / 112 (28.57%)		
number of deaths (all causes)	12		
number of deaths resulting from adverse events			

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
ACUTE LYMPHOCYTIC LEUKAEMIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ADENOCARCINOMA OF COLON			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CLEAR CELL RENAL CELL CARCINOMA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BENIGN NEOPLASM OF EPIDIDYMISS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BENIGN RENAL NEOPLASM			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BOWEN'S DISEASE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BREAST CANCER			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BASAL CELL CARCINOMA			
subjects affected / exposed	4 / 112 (3.57%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		



COLON CANCER				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COLORECTAL ADENOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ENDOMETRIAL CANCER				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
GALLBLADDER ADENOCARCINOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INVASIVE DUCTAL BREAST CARCINOMA				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
LYMPHOPROLIFERATIVE DISORDER				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LARYNGEAL SQUAMOUS CELL CARCINOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LUNG ADENOCARCINOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LUNG NEOPLASM MALIGNANT				

subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LUNG SQUAMOUS CELL CARCINOMA STAGE III				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
KERATOACANTHOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MALIGNANT MELANOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MENINGIOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MENINGIOMA BENIGN				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
NON-SMALL CELL LUNG CANCER				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
PAPILLARY THYROID CANCER				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
SQUAMOUS CELL CARCINOMA OF SKIN				

subjects affected / exposed	6 / 112 (5.36%)			
occurrences causally related to treatment / all	1 / 6			
deaths causally related to treatment / all	0 / 0			
RENAL CANCER				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
SKIN CANCER				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SMALL CELL LUNG CANCER METASTATIC				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SQUAMOUS CELL CARCINOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SQUAMOUS CELL CARCINOMA OF LUNG				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
RECTAL ADENOCARCINOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SQUAMOUS CELL CARCINOMA OF THE CERVIX				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SQUAMOUS CELL CARCINOMA OF				

THE TONGUE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TUMOUR FLARE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
UTERINE LEIOMYOMA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
AORTIC ANEURYSM RUPTURE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
AORTIC DISSECTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ARTERIAL THROMBOSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ARTERIOVENOUS FISTULA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYPOTENSION			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
BLEEDING VARICOSE VEIN			

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DEEP VEIN THROMBOSIS			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
HAEMATOMA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYPERTENSION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ARTERITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PHLEBITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
VASCULITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SUPERFICIAL VEIN THROMBOSIS			

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
THROMBOSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PHLEBITIS SUPERFICIAL			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
UMBILICAL HERNIA REPAIR			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
CHEST PAIN			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ASTHENIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ADVERSE DRUG REACTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CARDIAC DEATH			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

FATIGUE				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
FOREIGN BODY REACTION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
GENERAL PHYSICAL HEALTH DETERIORATION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HYPERTHERMIA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INFLUENZA LIKE ILLNESS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MALAISE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MUCOSAL INFLAMMATION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
OEDEMA PERIPHERAL				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PYREXIA				

subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
STRANGULATED HERNIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FACE OEDEMA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
ANAPHYLACTIC SHOCK			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ANAPHYLACTIC REACTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYPERSENSITIVITY			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DRUG HYPERSENSITIVITY			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
ANAPHYLACTOID REACTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			



CYSTOCELE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PENILE ADHESION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PROSTATITIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
ACUTE PULMONARY OEDEMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ASTHMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LARYNGEAL OEDEMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
CHRONIC OBSTRUCTIVE PULMONARY DISEASE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COUGH				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			

DYSPNOEA				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
INTERSTITIAL LUNG DISEASE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
BRONCHOPNEUMOPATHY				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LUNG DISORDER				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PLEURAL EFFUSION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PLEURITIC PAIN				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PNEUMONITIS				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
PULMONARY EMBOLISM				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
PULMONARY OEDEMA				

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RESPIRATORY FAILURE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMOTHORAX			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
CONVERSION DISORDER			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BIPOLAR DISORDER			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DEPRESSION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MANIA			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Product issues			
DEVICE BREAKAGE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			

PORTAL VEIN THROMBOSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HEPATITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CHOLECYSTITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CHOLECYSTITIS ACUTE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BILIARY DILATATION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BILIARY OBSTRUCTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CHOLANGITIS ACUTE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CHOLELITHIASIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			

ELECTROCARDIOGRAM T WAVE INVERSION			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
TROPONIN INCREASED			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TROPONIN T INCREASED			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
URINE OUTPUT DECREASED			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
WEIGHT DECREASED			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FIBRIN D DIMER INCREASED			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
AORTIC INJURY			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ACCIDENTAL OVERDOSE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

CHEST INJURY				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
FALL				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
FEMUR FRACTURE				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
HAND FRACTURE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HIP FRACTURE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HUMERUS FRACTURE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INCISIONAL HERNIA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INFUSION RELATED REACTION				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
LIGAMENT RUPTURE				

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MULTIPLE INJURIES			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
POSTOPERATIVE WOUND COMPLICATION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RADIUS FRACTURE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SPINAL COLUMN INJURY			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SPINAL COMPRESSION FRACTURE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SPINAL FRACTURE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ULNA FRACTURE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			

GASTROINTESTINAL MALFORMATION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BRUGADA SYNDROME			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ACUTE CORONARY SYNDROME			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CARDIOMYOPATHY			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CARDIAC FAILURE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CARDIAC ARREST			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BRADYCARDIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		



ATRIOVENTRICULAR BLOCK COMPLETE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ATRIAL FLUTTER				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ATRIAL FIBRILLATION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ARRHYTHMIA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
AORTIC VALVE INCOMPETENCE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
CARDIORENAL SYNDROME				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ANGINA PECTORIS				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
SINUS NODE DYSFUNCTION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PERICARDIAL EFFUSION				

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>PALPITATIONS</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>MYOCARDIAL ISCHAEMIA</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>MYOCARDIAL INFARCTION</b>			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>CORONARY ARTERY STENOSIS</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>CARDIOTOXICITY</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Nervous system disorders</b>			
<b>MIGRAINE WITH AURA</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>CEREBRAL INFARCTION</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>CEREBROVASCULAR ACCIDENT</b>			

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HEADACHE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ISCHAEMIC STROKE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CARPAL TUNNEL SYNDROME			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
OPTIC NEURITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SCIATICA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SEIZURE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SPEECH DISORDER			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TRANSIENT ISCHAEMIC ATTACK			

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SYNCOPE			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
AGRANULOCYTOSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
EOSINOPHILIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FEBRILE BONE MARROW APLASIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FEBRILE NEUTROPENIA			
subjects affected / exposed	6 / 112 (5.36%)		
occurrences causally related to treatment / all	6 / 6		
deaths causally related to treatment / all	0 / 0		
NEUTROPENIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PANCYTOPENIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
THROMBOCYTOPENIA			

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
IRON DEFICIENCY ANAEMIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
VERTIGO			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
RETINAL DETACHMENT			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PAPILLOEDEMA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CATARACT			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ABDOMINAL PAIN			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

DIARRHOEA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ASCITES				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COLITIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COLITIS ISCHAEMIC				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
CONSTIPATION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
GASTROINTESTINAL HAEMORRHAGE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
GASTRITIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
FAECALOMA				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ENTEROCOLITIS				

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>DIVERTICULUM INTESTINAL</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>GASTROINTESTINAL PAIN</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>OESOPHAGITIS</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>NAUSEA</b>			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INTESTINAL OBSTRUCTION</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>INGUINAL HERNIA</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>HERNIAL EVENTRATION</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>PANCREATITIS</b>			

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PANCREATITIS ACUTE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
POOR DENTAL CONDITION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
VOMITING			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
SUBILEUS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
CUTANEOUS VASCULITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CAPILLARITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS			



subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ECZEMA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYPERSENSITIVITY VASCULITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
NEUTROPHILIC DERMATOSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RASH			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
VASCULAR PURPURA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RASH PAPULAR			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
STEVENS-JOHNSON SYNDROME			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TOXIC SKIN ERUPTION			

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
URTICARIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RASH MACULO-PAPULAR			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CALCULUS URINARY			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CYSTITIS HAEMORRHAGIC			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
URINARY RETENTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYDRONEPHROSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
NEPHROLITHIASIS			

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
POLAKIURIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RENAL FAILURE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RENAL TUBULAR NECROSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HAEMATURIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
HYPERTHYROIDISM			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BACK PAIN			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

BONE PAIN				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
OSTEONECROSIS OF JAW				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
FLANK PAIN				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
INTERVERTEBRAL DISC PROTRUSION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
NECK PAIN				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
OSTEOARTHRITIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
CHONDROCALCINOSIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SOFT TISSUE NECROSIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SPINAL STENOSIS				

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SPONDYLITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
CELLULITIS			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CAMPYLOBACTER SEPSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BRONCHITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BRONCHIOLITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BACTERIURIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BACTERIAL SEPSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
APPENDICITIS			

subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
CLOSTRIDIUM DIFFICILE INFECTION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ESCHERICHIA SEPSIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ERYSIPELAS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ENTEROBACTER SEPSIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
DEVICE RELATED SEPSIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ESCHERICHIA URINARY TRACT INFECTION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
GASTROENTERITIS VIRAL				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
GASTROENTERITIS				

subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>GANGRENE</b>				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>FUSOBACTERIUM INFECTION</b>				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>GENITAL HERPES SIMPLEX</b>				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>H1N1 INFLUENZA</b>				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>OESOPHAGEAL CANDIDIASIS</b>				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>MENINGITIS</b>				
subjects affected / exposed	1 / 112 (0.89%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>LARGE INTESTINE INFECTION</b>				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>INFLUENZA</b>				

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
INFECTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HUMAN EHRLICHIOSIS			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
HERPES ZOSTER			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HERPES OPHTHALMIC			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HEPATITIS E			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PARONYCHIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMONIA HAEMOPHILUS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMONIA PNEUMOCOCCAL			



subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMONIA STAPHYLOCOCCAL			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMONIA STREPTOCOCCAL			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMONIA VIRAL			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMOCYSTIS JIROVECII PNEUMONIA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PILONIDAL DISEASE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PHARYNGITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PERITONITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMONIA			

subjects affected / exposed	3 / 112 (2.68%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
PSEUDOMONAL SEPSIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PSEUDOMONAS INFECTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TOOTH ABSCESS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TONSILLITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SOFT TISSUE INFECTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SINUSITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SEPTIC SHOCK			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SEPSIS			

subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
RESPIRATORY TRACT INFECTION				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PYELONEPHRITIS ACUTE				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PYELONEPHRITIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
WOUND INFECTION STAPHYLOCOCCAL				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
WOUND INFECTION BACTERIAL				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
UROSEPSIS				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
URINARY TRACT INFECTION ENTEROCOCCAL				
subjects affected / exposed	0 / 112 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
URINARY TRACT INFECTION				

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
VIRAL INFECTION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DEHYDRATION			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DIABETES MELLITUS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DIABETES MELLITUS INADEQUATE CONTROL			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DIABETIC KETOACIDOSIS			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
HYPONATRAEMIA			

subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>HYPERGLYCAEMIA</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>HYPERKALAEMIA</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>HYPOALBUMINAEMIA</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>HYPOKALAEMIA</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>HYPERCALCAEMIA</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>MALNUTRITION</b>			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>TUMOUR LYSIS SYNDROME</b>			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Investigator's Choice: Rituximab- CHOP	Investigator's Choice: Rituximab- CVP	Rituximab- Lenalidomide
Total subjects affected by non-serious adverse events			
subjects affected / exposed	351 / 365 (96.16%)	26 / 26 (100.00%)	496 / 507 (97.83%)
<b>Vascular disorders</b>			
<b>HOT FLUSH</b>			
subjects affected / exposed	5 / 365 (1.37%)	0 / 26 (0.00%)	16 / 507 (3.16%)
occurrences (all)	5	0	17
<b>PHLEBITIS</b>			
subjects affected / exposed	4 / 365 (1.10%)	0 / 26 (0.00%)	2 / 507 (0.39%)
occurrences (all)	4	0	2
<b>HYPOTENSION</b>			
subjects affected / exposed	5 / 365 (1.37%)	2 / 26 (7.69%)	16 / 507 (3.16%)
occurrences (all)	6	2	18
<b>HYPERTENSION</b>			
subjects affected / exposed	13 / 365 (3.56%)	2 / 26 (7.69%)	23 / 507 (4.54%)
occurrences (all)	15	2	27
<b>General disorders and administration site conditions</b>			
<b>PYREXIA</b>			
subjects affected / exposed	43 / 365 (11.78%)	4 / 26 (15.38%)	90 / 507 (17.75%)
occurrences (all)	52	5	110
<b>PAIN</b>			
subjects affected / exposed	9 / 365 (2.47%)	2 / 26 (7.69%)	9 / 507 (1.78%)
occurrences (all)	10	2	10
<b>OEDEMA PERIPHERAL</b>			
subjects affected / exposed	31 / 365 (8.49%)	4 / 26 (15.38%)	68 / 507 (13.41%)
occurrences (all)	33	4	84
<b>MUCOSAL INFLAMMATION</b>			
subjects affected / exposed	19 / 365 (5.21%)	0 / 26 (0.00%)	15 / 507 (2.96%)
occurrences (all)	25	0	23
<b>MALAISE</b>			
subjects affected / exposed	8 / 365 (2.19%)	0 / 26 (0.00%)	11 / 507 (2.17%)
occurrences (all)	8	0	12
<b>INFLUENZA LIKE ILLNESS</b>			

subjects affected / exposed occurrences (all)	5 / 365 (1.37%) 7	0 / 26 (0.00%) 0	18 / 507 (3.55%) 19
FATIGUE subjects affected / exposed occurrences (all)	67 / 365 (18.36%) 80	6 / 26 (23.08%) 7	116 / 507 (22.88%) 155
CHILLS subjects affected / exposed occurrences (all)	2 / 365 (0.55%) 4	1 / 26 (3.85%) 1	20 / 507 (3.94%) 22
ASTHENIA subjects affected / exposed occurrences (all)	129 / 365 (35.34%) 168	6 / 26 (23.08%) 7	144 / 507 (28.40%) 194
Respiratory, thoracic and mediastinal disorders DYSпноEA EXERTIONAL subjects affected / exposed occurrences (all)	3 / 365 (0.82%) 3	2 / 26 (7.69%) 2	4 / 507 (0.79%) 4
DYSпноEA subjects affected / exposed occurrences (all)	33 / 365 (9.04%) 36	5 / 26 (19.23%) 8	55 / 507 (10.85%) 74
COUGH subjects affected / exposed occurrences (all)	44 / 365 (12.05%) 57	4 / 26 (15.38%) 5	104 / 507 (20.51%) 128
RHINITIS ALLERGIC subjects affected / exposed occurrences (all)	5 / 365 (1.37%) 5	0 / 26 (0.00%) 0	12 / 507 (2.37%) 12
PRODUCTIVE COUGH subjects affected / exposed occurrences (all)	3 / 365 (0.82%) 3	2 / 26 (7.69%) 2	12 / 507 (2.37%) 15
OROPHARYNGEAL PAIN subjects affected / exposed occurrences (all)	14 / 365 (3.84%) 14	1 / 26 (3.85%) 1	25 / 507 (4.93%) 27
Psychiatric disorders INSOMNIA subjects affected / exposed occurrences (all)	34 / 365 (9.32%) 39	3 / 26 (11.54%) 3	31 / 507 (6.11%) 33
DEPRESSION			

subjects affected / exposed	21 / 365 (5.75%)	2 / 26 (7.69%)	20 / 507 (3.94%)
occurrences (all)	22	2	20
ANXIETY			
subjects affected / exposed	24 / 365 (6.58%)	0 / 26 (0.00%)	27 / 507 (5.33%)
occurrences (all)	24	0	30
Investigations			
LYMPHOCYTE COUNT DECREASED			
subjects affected / exposed	6 / 365 (1.64%)	2 / 26 (7.69%)	4 / 507 (0.79%)
occurrences (all)	12	2	6
WEIGHT DECREASED			
subjects affected / exposed	13 / 365 (3.56%)	2 / 26 (7.69%)	19 / 507 (3.75%)
occurrences (all)	13	2	22
WEIGHT INCREASED			
subjects affected / exposed	7 / 365 (1.92%)	2 / 26 (7.69%)	8 / 507 (1.58%)
occurrences (all)	7	3	9
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed	44 / 365 (12.05%)	0 / 26 (0.00%)	14 / 507 (2.76%)
occurrences (all)	93	0	21
Injury, poisoning and procedural complications			
INFUSION RELATED REACTION			
subjects affected / exposed	25 / 365 (6.85%)	1 / 26 (3.85%)	58 / 507 (11.44%)
occurrences (all)	35	1	73
Cardiac disorders			
PALPITATIONS			
subjects affected / exposed	9 / 365 (2.47%)	0 / 26 (0.00%)	7 / 507 (1.38%)
occurrences (all)	10	0	7
Nervous system disorders			
PERIPHERAL SENSORY NEUROPATHY			
subjects affected / exposed	21 / 365 (5.75%)	3 / 26 (11.54%)	18 / 507 (3.55%)
occurrences (all)	22	3	23
PARAESTHESIA			
subjects affected / exposed	46 / 365 (12.60%)	3 / 26 (11.54%)	37 / 507 (7.30%)
occurrences (all)	50	3	44
NEUROPATHY PERIPHERAL			
subjects affected / exposed	72 / 365 (19.73%)	2 / 26 (7.69%)	35 / 507 (6.90%)
occurrences (all)	74	2	37



HYPOAESTHESIA			
subjects affected / exposed	8 / 365 (2.19%)	0 / 26 (0.00%)	8 / 507 (1.58%)
occurrences (all)	9	0	8
HEADACHE			
subjects affected / exposed	31 / 365 (8.49%)	3 / 26 (11.54%)	66 / 507 (13.02%)
occurrences (all)	49	6	81
DYSGEUSIA			
subjects affected / exposed	24 / 365 (6.58%)	0 / 26 (0.00%)	23 / 507 (4.54%)
occurrences (all)	26	0	24
DIZZINESS			
subjects affected / exposed	17 / 365 (4.66%)	0 / 26 (0.00%)	45 / 507 (8.88%)
occurrences (all)	20	0	55
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	44 / 365 (12.05%)	3 / 26 (11.54%)	25 / 507 (4.93%)
occurrences (all)	56	5	36
LEUKOPENIA			
subjects affected / exposed	47 / 365 (12.88%)	2 / 26 (7.69%)	22 / 507 (4.34%)
occurrences (all)	82	2	60
THROMBOCYTOPENIA			
subjects affected / exposed	14 / 365 (3.84%)	0 / 26 (0.00%)	17 / 507 (3.35%)
occurrences (all)	20	0	21
NEUTROPENIA			
subjects affected / exposed	172 / 365 (47.12%)	7 / 26 (26.92%)	199 / 507 (39.25%)
occurrences (all)	373	16	467
LYMPHOPENIA			
subjects affected / exposed	19 / 365 (5.21%)	1 / 26 (3.85%)	7 / 507 (1.38%)
occurrences (all)	30	1	22
Gastrointestinal disorders			
NAUSEA			
subjects affected / exposed	128 / 365 (35.07%)	7 / 26 (26.92%)	100 / 507 (19.72%)
occurrences (all)	202	12	147
GASTROOESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	15 / 365 (4.11%)	0 / 26 (0.00%)	18 / 507 (3.55%)
occurrences (all)	17	0	20
DYSPEPSIA			

subjects affected / exposed	19 / 365 (5.21%)	2 / 26 (7.69%)	26 / 507 (5.13%)
occurrences (all)	20	2	28
DIARRHOEA			
subjects affected / exposed	50 / 365 (13.70%)	6 / 26 (23.08%)	184 / 507 (36.29%)
occurrences (all)	66	7	309
CONSTIPATION			
subjects affected / exposed	109 / 365 (29.86%)	13 / 26 (50.00%)	179 / 507 (35.31%)
occurrences (all)	140	15	244
ABDOMINAL PAIN			
subjects affected / exposed	29 / 365 (7.95%)	2 / 26 (7.69%)	77 / 507 (15.19%)
occurrences (all)	41	2	98
ABDOMINAL PAIN UPPER			
subjects affected / exposed	45 / 365 (12.33%)	1 / 26 (3.85%)	37 / 507 (7.30%)
occurrences (all)	50	1	42
VOMITING			
subjects affected / exposed	61 / 365 (16.71%)	2 / 26 (7.69%)	32 / 507 (6.31%)
occurrences (all)	76	3	42
STOMATITIS			
subjects affected / exposed	26 / 365 (7.12%)	1 / 26 (3.85%)	15 / 507 (2.96%)
occurrences (all)	38	1	23
Skin and subcutaneous tissue disorders			
RASH MACULO-PAPULAR			
subjects affected / exposed	5 / 365 (1.37%)	1 / 26 (3.85%)	19 / 507 (3.75%)
occurrences (all)	5	1	20
RASH			
subjects affected / exposed	22 / 365 (6.03%)	1 / 26 (3.85%)	141 / 507 (27.81%)
occurrences (all)	26	1	194
PRURITUS			
subjects affected / exposed	22 / 365 (6.03%)	3 / 26 (11.54%)	86 / 507 (16.96%)
occurrences (all)	24	3	99
NIGHT SWEATS			
subjects affected / exposed	4 / 365 (1.10%)	2 / 26 (7.69%)	18 / 507 (3.55%)
occurrences (all)	4	2	19
ERYTHEMA			
subjects affected / exposed	9 / 365 (2.47%)	2 / 26 (7.69%)	38 / 507 (7.50%)
occurrences (all)	10	3	43

ALOPECIA			
subjects affected / exposed	39 / 365 (10.68%)	2 / 26 (7.69%)	5 / 507 (0.99%)
occurrences (all)	40	2	5
DRY SKIN			
subjects affected / exposed	13 / 365 (3.56%)	0 / 26 (0.00%)	44 / 507 (8.68%)
occurrences (all)	15	0	47
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	52 / 365 (14.25%)	4 / 26 (15.38%)	79 / 507 (15.58%)
occurrences (all)	57	4	90
BACK PAIN			
subjects affected / exposed	49 / 365 (13.42%)	5 / 26 (19.23%)	75 / 507 (14.79%)
occurrences (all)	63	6	87
BONE PAIN			
subjects affected / exposed	37 / 365 (10.14%)	1 / 26 (3.85%)	22 / 507 (4.34%)
occurrences (all)	42	1	22
MUSCLE SPASMS			
subjects affected / exposed	16 / 365 (4.38%)	2 / 26 (7.69%)	70 / 507 (13.81%)
occurrences (all)	20	2	81
MYALGIA			
subjects affected / exposed	16 / 365 (4.38%)	2 / 26 (7.69%)	73 / 507 (14.40%)
occurrences (all)	21	2	103
PAIN IN EXTREMITY			
subjects affected / exposed	15 / 365 (4.11%)	2 / 26 (7.69%)	39 / 507 (7.69%)
occurrences (all)	15	2	40
Infections and infestations			
FUNGAL INFECTION			
subjects affected / exposed	3 / 365 (0.82%)	2 / 26 (7.69%)	5 / 507 (0.99%)
occurrences (all)	3	2	5
CONJUNCTIVITIS			
subjects affected / exposed	23 / 365 (6.30%)	2 / 26 (7.69%)	15 / 507 (2.96%)
occurrences (all)	24	2	19
BRONCHITIS			
subjects affected / exposed	79 / 365 (21.64%)	5 / 26 (19.23%)	83 / 507 (16.37%)
occurrences (all)	104	7	126
GASTROENTERITIS			

subjects affected / exposed	10 / 365 (2.74%)	2 / 26 (7.69%)	24 / 507 (4.73%)
occurrences (all)	10	2	27
HERPES ZOSTER			
subjects affected / exposed	14 / 365 (3.84%)	0 / 26 (0.00%)	8 / 507 (1.58%)
occurrences (all)	14	0	9
INFLUENZA			
subjects affected / exposed	17 / 365 (4.66%)	2 / 26 (7.69%)	23 / 507 (4.54%)
occurrences (all)	17	2	25
NASOPHARYNGITIS			
subjects affected / exposed	42 / 365 (11.51%)	2 / 26 (7.69%)	87 / 507 (17.16%)
occurrences (all)	58	2	112
PHARYNGITIS			
subjects affected / exposed	17 / 365 (4.66%)	2 / 26 (7.69%)	19 / 507 (3.75%)
occurrences (all)	17	2	21
RHINITIS			
subjects affected / exposed	34 / 365 (9.32%)	0 / 26 (0.00%)	56 / 507 (11.05%)
occurrences (all)	41	0	69
SINUSITIS			
subjects affected / exposed	20 / 365 (5.48%)	2 / 26 (7.69%)	42 / 507 (8.28%)
occurrences (all)	24	2	50
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	22 / 365 (6.03%)	5 / 26 (19.23%)	48 / 507 (9.47%)
occurrences (all)	24	7	69
URINARY TRACT INFECTION			
subjects affected / exposed	27 / 365 (7.40%)	0 / 26 (0.00%)	44 / 507 (8.68%)
occurrences (all)	41	0	65
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	14 / 365 (3.84%)	1 / 26 (3.85%)	19 / 507 (3.75%)
occurrences (all)	19	1	20

<b>Non-serious adverse events</b>	Investigator's Choice: Rituximab-Bendamustine		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	108 / 112 (96.43%)		
Vascular disorders			

HOT FLUSH			
subjects affected / exposed	6 / 112 (5.36%)		
occurrences (all)	6		
PHLEBITIS			
subjects affected / exposed	6 / 112 (5.36%)		
occurrences (all)	6		
HYPOTENSION			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences (all)	1		
HYPERTENSION			
subjects affected / exposed	9 / 112 (8.04%)		
occurrences (all)	9		
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	23 / 112 (20.54%)		
occurrences (all)	28		
PAIN			
subjects affected / exposed	4 / 112 (3.57%)		
occurrences (all)	4		
OEDEMA PERIPHERAL			
subjects affected / exposed	12 / 112 (10.71%)		
occurrences (all)	17		
MUCOSAL INFLAMMATION			
subjects affected / exposed	2 / 112 (1.79%)		
occurrences (all)	3		
MALAISE			
subjects affected / exposed	6 / 112 (5.36%)		
occurrences (all)	6		
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	7 / 112 (6.25%)		
occurrences (all)	8		
FATIGUE			
subjects affected / exposed	73 / 112 (65.18%)		
occurrences (all)	111		
CHILLS			

subjects affected / exposed	11 / 112 (9.82%)		
occurrences (all)	12		
ASTHENIA			
subjects affected / exposed	5 / 112 (4.46%)		
occurrences (all)	5		
Respiratory, thoracic and mediastinal disorders			
DYSпноEA EXERTIONAL			
subjects affected / exposed	4 / 112 (3.57%)		
occurrences (all)	4		
DYSпноEA			
subjects affected / exposed	13 / 112 (11.61%)		
occurrences (all)	16		
COUGH			
subjects affected / exposed	20 / 112 (17.86%)		
occurrences (all)	25		
RHINITIS ALLERGIC			
subjects affected / exposed	8 / 112 (7.14%)		
occurrences (all)	9		
PRODUCTIVE COUGH			
subjects affected / exposed	3 / 112 (2.68%)		
occurrences (all)	3		
OROPHARYNGEAL PAIN			
subjects affected / exposed	10 / 112 (8.93%)		
occurrences (all)	10		
Psychiatric disorders			
INSOMNIA			
subjects affected / exposed	21 / 112 (18.75%)		
occurrences (all)	26		
DEPRESSION			
subjects affected / exposed	8 / 112 (7.14%)		
occurrences (all)	8		
ANXIETY			
subjects affected / exposed	11 / 112 (9.82%)		
occurrences (all)	12		
Investigations			

LYMPHOCYTE COUNT DECREASED subjects affected / exposed occurrences (all)	2 / 112 (1.79%) 2		
WEIGHT DECREASED subjects affected / exposed occurrences (all)	9 / 112 (8.04%) 9		
WEIGHT INCREASED subjects affected / exposed occurrences (all)	1 / 112 (0.89%) 1		
WHITE BLOOD CELL COUNT DECREASED subjects affected / exposed occurrences (all)	4 / 112 (3.57%) 5		
Injury, poisoning and procedural complications INFUSION RELATED REACTION subjects affected / exposed occurrences (all)	29 / 112 (25.89%) 31		
Cardiac disorders PALPITATIONS subjects affected / exposed occurrences (all)	6 / 112 (5.36%) 6		
Nervous system disorders PERIPHERAL SENSORY NEUROPATHY subjects affected / exposed occurrences (all)	5 / 112 (4.46%) 5		
PARAESTHESIA subjects affected / exposed occurrences (all)	8 / 112 (7.14%) 9		
NEUROPATHY PERIPHERAL subjects affected / exposed occurrences (all)	6 / 112 (5.36%) 12		
HYPOAESTHESIA subjects affected / exposed occurrences (all)	6 / 112 (5.36%) 7		
HEADACHE subjects affected / exposed occurrences (all)	25 / 112 (22.32%) 31		

DYSGEUSIA			
subjects affected / exposed	5 / 112 (4.46%)		
occurrences (all)	5		
DIZZINESS			
subjects affected / exposed	20 / 112 (17.86%)		
occurrences (all)	29		
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	8 / 112 (7.14%)		
occurrences (all)	16		
LEUKOPENIA			
subjects affected / exposed	7 / 112 (6.25%)		
occurrences (all)	11		
THROMBOCYTOPENIA			
subjects affected / exposed	11 / 112 (9.82%)		
occurrences (all)	13		
NEUTROPENIA			
subjects affected / exposed	25 / 112 (22.32%)		
occurrences (all)	41		
LYMPHOPENIA			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences (all)	1		
Gastrointestinal disorders			
NAUSEA			
subjects affected / exposed	72 / 112 (64.29%)		
occurrences (all)	124		
GASTROESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	7 / 112 (6.25%)		
occurrences (all)	7		
DYSPEPSIA			
subjects affected / exposed	7 / 112 (6.25%)		
occurrences (all)	8		
DIARRHOEA			
subjects affected / exposed	37 / 112 (33.04%)		
occurrences (all)	65		
CONSTIPATION			



subjects affected / exposed	43 / 112 (38.39%)		
occurrences (all)	62		
ABDOMINAL PAIN			
subjects affected / exposed	12 / 112 (10.71%)		
occurrences (all)	13		
ABDOMINAL PAIN UPPER			
subjects affected / exposed	6 / 112 (5.36%)		
occurrences (all)	6		
VOMITING			
subjects affected / exposed	31 / 112 (27.68%)		
occurrences (all)	56		
STOMATITIS			
subjects affected / exposed	9 / 112 (8.04%)		
occurrences (all)	10		
Skin and subcutaneous tissue disorders			
RASH MACULO-PAPULAR			
subjects affected / exposed	6 / 112 (5.36%)		
occurrences (all)	6		
RASH			
subjects affected / exposed	19 / 112 (16.96%)		
occurrences (all)	22		
PRURITUS			
subjects affected / exposed	10 / 112 (8.93%)		
occurrences (all)	15		
NIGHT SWEATS			
subjects affected / exposed	11 / 112 (9.82%)		
occurrences (all)	13		
ERYTHEMA			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences (all)	0		
ALOPECIA			
subjects affected / exposed	4 / 112 (3.57%)		
occurrences (all)	4		
DRY SKIN			
subjects affected / exposed	4 / 112 (3.57%)		
occurrences (all)	6		

Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	24 / 112 (21.43%)		
occurrences (all)	27		
BACK PAIN			
subjects affected / exposed	11 / 112 (9.82%)		
occurrences (all)	13		
BONE PAIN			
subjects affected / exposed	3 / 112 (2.68%)		
occurrences (all)	5		
MUSCLE SPASMS			
subjects affected / exposed	3 / 112 (2.68%)		
occurrences (all)	3		
MYALGIA			
subjects affected / exposed	12 / 112 (10.71%)		
occurrences (all)	15		
PAIN IN EXTREMITY			
subjects affected / exposed	6 / 112 (5.36%)		
occurrences (all)	7		
Infections and infestations			
FUNGAL INFECTION			
subjects affected / exposed	3 / 112 (2.68%)		
occurrences (all)	5		
CONJUNCTIVITIS			
subjects affected / exposed	4 / 112 (3.57%)		
occurrences (all)	4		
BRONCHITIS			
subjects affected / exposed	6 / 112 (5.36%)		
occurrences (all)	7		
GASTROENTERITIS			
subjects affected / exposed	1 / 112 (0.89%)		
occurrences (all)	1		
HERPES ZOSTER			
subjects affected / exposed	11 / 112 (9.82%)		
occurrences (all)	11		
INFLUENZA			

subjects affected / exposed	2 / 112 (1.79%)		
occurrences (all)	2		
NASOPHARYNGITIS			
subjects affected / exposed	8 / 112 (7.14%)		
occurrences (all)	10		
PHARYNGITIS			
subjects affected / exposed	2 / 112 (1.79%)		
occurrences (all)	2		
RHINITIS			
subjects affected / exposed	0 / 112 (0.00%)		
occurrences (all)	0		
SINUSITIS			
subjects affected / exposed	11 / 112 (9.82%)		
occurrences (all)	13		
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	28 / 112 (25.00%)		
occurrences (all)	37		
URINARY TRACT INFECTION			
subjects affected / exposed	9 / 112 (8.04%)		
occurrences (all)	10		
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	10 / 112 (8.93%)		
occurrences (all)	11		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 June 2012	Secondary endpoints updated.
08 February 2016	Changed the timing of CR/CRu at 120 weeks from N = 644 to all randomized subjects. Added an interim analysis for PFS Add CR at 120 weeks as the first secondary endpoint
21 April 2016	Re-insertion of Sections 13 .4 .1 and 13 .4 .2.
25 February 2019	Reduced the frequency of computed tomography (CT) scans during follow up (FU) visits.
08 January 2024	Included an additional criterion, which is time-driven, to the existing criterion, which is event-driven, to trigger the final progression-free survival (PFS; co-primary endpoint) analysis and therefore the end of the study.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported